Researchers have developed a groundbreaking method combining test-time augmentation and conformal prediction, enhancing AI model reliability by up to 30% for critical tasks like medical diagnosis, enabling more accurate and efficient decision-making in high-stakes scenarios.
Researchers developed a machine-learning model that can predict the transition states of chemical reactions in under a second with high accuracy, enabling efficient design of useful compounds like fuels and drugs by rapidly exploring potential reaction pathways.
In a groundbreaking development, researchers have harnessed the power of AI and machine learning to analyze patient data, enabling the prediction of Alzheimer's disease up to 7 years before symptoms manifest, with high cholesterol and osteoporosis emerging as key predictors.
Breakthrough AI tools developed by Cambridge researchers can accurately predict cystic fibrosis progression, enabling personalized treatment plans tailored to individual patients' disease trajectories, competing health risks, and past cases, representing a major step towards precision healthcare.
In a groundbreaking achievement, scientists have developed an AI model that mimics the mouse brain's visual cortex, enabling virtual neuroscience experiments with the potential to accelerate research by accurately predicting the responses of tens of thousands of neurons to new visual stimuli.
A groundbreaking Israeli AI model trained on global satellite data accurately predicts lightning-sparked wildfire ignition locations with over 90% precision, providing a crucial tool for targeted wildfire prevention amid escalating climate change risks.
In a groundbreaking collaboration, Ai2 and Google Cloud have jointly invested $20 million to establish the Cancer AI Alliance, leveraging AI's potential to accelerate cancer research through shared models and secure data analytics powered by Google's cloud infrastructure.
Google-backed AI drug discovery startup Isomorphic Labs secured a staggering $600 million in funding led by Thrive Capital, fueling its AI engine's development and advancing partnerships with pharmaceutical giants like Eli Lilly and Novartis worth billions to revolutionize drug design.
Alphabet's AI drug discovery subsidiary Isomorphic Labs secures $600 million funding from Thrive Capital to accelerate development of its AI-powered drug design platform and advance its drug candidates into clinical trials, leveraging technology like DeepMind's AlphaFold.
An AI algorithm trained on 80,000 cases optimizes intravenous nutrition for premature babies, reducing medical errors and costs while enhancing care efficiency and accessibility by assisting doctors in making better clinical decisions for this vulnerable population.